请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
banner
当前位置: 首页 > 产品中心 > Angiogenesis > MedKoo/Afatinib free basefeatured/100mg/200500

MedKoo/Afatinib free basefeatured/100mg/200500

  • 产品编号: 200500
  • 美  元  价: $90.00
  • 市  场  价: ¥1800.00
  • 品       牌:
  • 产       地: 美国(厂家直采)
  • 公       司: MedKoo Biosciences, Inc
  • 产品分类:
  • 公司分类: Angiogenesis
MedKoo/Afatinib free basefeatured/100mg/200500
  • MedKoo/Afatinib free basefeatured/100mg/200500
商品介绍

Afatinib free base
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:200500

CAS#:850140-72-6 (free base)

Description:Afatinib, also know as BIBW 2992, is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Afatinib is approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an angiokinase inhibitor.

Price and Availability

SizePriceShipping out timeQuantity
100mgUSD 90Same Day
200mgUSD 150Same Day
500mgUSD 250Same Day
1gUSD 450Same Day
2gUSD 850Same Day
5gUSD 1650Same Day
10gUSD 2650Same Day
20gUSD 3650Same Day
50gUSD 46502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Afatinib free base, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 200500Name: Afatinib free baseCAS#: 850140-72-6 (free base)Chemical Formula: C24H25ClFN5O3Exact Mass: 485.163Molecular Weight: 485.94Elemental Analysis: C, 59.32; H, 5.19; Cl, 7.30; F, 3.91; N, 14.41; O, 9.88

Related CAS #:850140-73-7 (dimaleate)439081-18-2 (free base)850140-72-6 (free base)

Synonym:BIBW-2992; BIBW 2992; BIBW2992. Afatinib free base; trade name: Gilotrif, Tomtovok and Tovok.

IUPAC/Chemical Name:(S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.

InChi Key:ULXXDDBFHOBEHA-CWDCEQMOSA-N

InChi Code:InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

SMILES Code:O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C

Technical Data

Appearance:
White to light yellow solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#XPR70102

QC Data:
View QC data: current batch, Lot#XPR70102

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

Related: 439081-18-2(Afatinib free base);850140-73-7 (Afatinib dimaleate)

As of July 2012, it is undergoing Phase III clinical trials for this indication and breast cancer, as well as Phase II trials for prostate  and head and neck cancer,  and a Phase I glioma trial.  Afatinib is not a first-line treatment; it is only used after other therapies have failed. In October 2010 a Phase III trial in NSCLC patients called Lux-Lung 5 began with this drug. Fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.  In May 2012, the Phase IIb/III trial Lux-Lung 1 came to the same conclusion. Phase II results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (Her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib. Double-blind Phase III trials are under way to confirm or refute this finding. Her2-negative breast cancers showed limited or no response to the drug.   

References

 1: Belani CP. The role of irreversible EGFRinhibitors in the treatment of non-small cell lung cancer: overcomingresistance to reversible EGFR inhibitors. Cancer Invest. 2010May;28(4):413-23. Review. PubMed PMID: 20307200.

2: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find ExpClin Pharmacol. 2009 Dec;31(10):661-700. PubMed PMID: 20140276.

3: Gazdar AF. Epidermal growth factor receptor inhibition in lungcancer: the evolving role of individualized therapy. Cancer MetastasisRev. 2010 Mar;29(1):37-48. Review. PubMed PMID: 20127143.

4: Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Klüter S, Pawar VG,Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M,Simard JR, Getlik M, Yuza Y, Chen TH, Greulich H, Thomas RK, Rauh D.Chemogenomic profiling provides insights into the limited activity ofirreversible EGFR Inhibitors in tumor cells expressing the T790M EGFRresistance mutation. Cancer Res. 2010 Feb 1;70(3):868-74. Epub 2010 Jan26. PubMed PMID: 20103621.

5: Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategiesto overcome limitations of reversible EGFR tyrosine kinase inhibitortherapy in non-small cell lung cancer. Lung Cancer. 2010 Jan 19. [Epubahead of print] PubMed PMID: 20092908.

6: Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A,Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF,Politi KA, Pao W. Dual targeting of EGFR can overcome a major drugresistance mutation in mouse models of EGFR mutant lung cancer. J ClinInvest. 2009 Oct;119(10):3000-10. doi: 10.1172/JCI38746. Epub 2009 Sep14. PubMed PMID: 19759520; PubMed Central PMCID: PMC2752070.

7: Ocaña A, Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors andbreast cancer: current status and future directions. Cancer Treat Rev.2009 Dec;35(8):685-91. Epub 2009 Sep 4. Review. PubMed PMID: 19733440.

8: Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermalgrowth factor receptor tyrosine kinase inhibitors in non-small-cell lungcancers dependent on the epidermal growth factor receptor pathway. ClinLung Cancer. 2009 Jul;10(4):281-9. Review. PubMed PMID: 19632948; PubMedCentral PMCID: PMC2758558.

9: Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL,Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF,Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG,Solca F, Wistuba II, Wong KK. HER2YVMA drives rapid development ofadenosquamous lung tumors in mice that are sensitive to BIBW2992 andrapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan13;106(2):474-9. Epub 2009 Jan 2. PubMed PMID: 19122144; PubMed CentralPMCID: PMC2626727.

10: Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinaseinhibitor for the treatment of solid tumors. Curr Opin Investig Drugs.2008 Dec;9(12):1336-46. Review. PubMed PMID: 19037840.

品牌介绍


MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。




蚂蚁淘(ebiomall)作为一家生命科学领域的垂直电商平台,公司专注生物医学科研用品的全球导购和品牌推广,为海内外厂方与代理经销商搭建跨境贸易系统和交流平台。产品齐全,200+分类,1000+品牌,500万+产品信息。100%正品,专业售后,到货快,在线下单, 简单轻松,节省科学家宝贵的科研时间。为您竭诚服务!

【订购】蚂蚁淘生物科技  联系方式:4000-520-616

更多产品,更多优惠!请联系我们!

苏州蚂蚁淘生物科技有限公司

免费热线:4000-520-616

官网:https://www.ebiomall.cn/



MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采模式 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔
在线客服
客服电话

4000-520-616

0512-67156496